* Augmedix Inc reported a quarterly adjusted loss of 13 cents per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of -12 cents. The mean expectation of three analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -15 cents to -12 cents per share.
* Revenue rose 26.8% to $13.66 million from a year ago; analysts expected $13.64 million.
* Augmedix Inc's reported EPS for the quarter was a loss of 16 cents.
* The company reported a quarterly loss of $8.36 million.
* Augmedix Inc shares had risen by 158.0% this quarter and lost 61.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 4.2% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the business support services peer group is also "buy"
Wall Street's median 12-month price target for Augmedix Inc is $2.93 This summary was machine generated from LSEG data August 13 at 01:15 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.13 -0.13 Met
Mar. 31 2024 -0.13 -0.12 Beat
Dec. 31 2023 -0.10 -0.09 Beat
Sep. 30 2023 -0.12 -0.10 Beat
Comments